Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CL Stock Forecast 2025-2026
$78.07
Current Price
$63.10B
Market Cap
Buy 13
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to CL Price Targets
+21.7%
To High Target of $95.00
+12.7%
To Median Target of $88.00
-1.4%
To Low Target of $77.00
CL Price Momentum
-2.9%
1 Week Change
-0.9%
1 Month Change
-17.1%
1 Year Change
-14.1%
Year-to-Date Change
-22.1%
From 52W High of $100.18
+4.7%
From 52W Low of $74.55
📊 TOP ANALYST CALLS
Did CL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Colgate is one of their latest high-conviction picks.
Latest CL Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, CL has a bullish consensus with a median price target of $88.00 (ranging from $77.00 to $95.00). The overall analyst rating is Buy (7.8/10). Currently trading at $78.07, the median forecast implies a 12.7% upside. This outlook is supported by 13 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Filippo Falorni at Citigroup, projecting a 21.7% upside. Conversely, the most conservative target is provided by Chris Carey at Wells Fargo, suggesting a 1.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CL Analyst Ratings
13
Buy
7
Hold
1
Sell
CL Price Target Range
Low
$77.00
Average
$88.00
High
$95.00
Current: $78.07
Latest CL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $80.00 |
| Nov 3, 2025 | Citigroup | Filippo Falorni | Buy | Maintains | $95.00 |
| Nov 3, 2025 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $87.00 |
| Nov 3, 2025 | Evercore ISI Group | Robert Ottenstein | Outperform | Maintains | $94.00 |
| Nov 3, 2025 | Morgan Stanley | Dara Mohsenian | Overweight | Maintains | $87.00 |
| Nov 3, 2025 | Wells Fargo | Chris Carey | Underweight | Maintains | $77.00 |
| Nov 3, 2025 | UBS | Peter Grom | Buy | Maintains | $90.00 |
| Oct 20, 2025 | Raymond James | Olivia Tong | Outperform | Maintains | $95.00 |
| Oct 10, 2025 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $88.00 |
| Oct 8, 2025 | B of A Securities | Bryan Spillane | Buy | Maintains | $88.00 |
| Oct 8, 2025 | UBS | Peter Grom | Buy | Maintains | $92.00 |
| Oct 3, 2025 | Piper Sandler | Michael Lavery | Neutral | Assumes | $84.00 |
| Oct 2, 2025 | Goldman Sachs | Jason English | Buy | Maintains | $91.00 |
| Oct 1, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $82.00 |
| Sep 25, 2025 | Wells Fargo | Chris Carey | Underweight | Maintains | $80.00 |
| Aug 4, 2025 | Wells Fargo | Chris Carey | Underweight | Maintains | $83.00 |
| Aug 4, 2025 | Morgan Stanley | Dara Mohsenian | Overweight | Maintains | $96.00 |
| Aug 4, 2025 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $95.00 |
| Aug 4, 2025 | Citigroup | Filippo Falorni | Buy | Maintains | $105.00 |
| Jul 25, 2025 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $99.00 |
Colgate-Palmolive Co. (CL) Competitors
The following stocks are similar to Colgate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Colgate-Palmolive Co. (CL) Financial Data
Colgate-Palmolive Co. has a market capitalization of $63.10B with a P/E ratio of 21.9x. The company generates $20.10B in trailing twelve-month revenue with a 14.5% profit margin.
Revenue growth is +1.9% quarter-over-quarter, while maintaining an operating margin of +20.2% and return on equity of +293.6%.
Valuation Metrics
Market Cap
$63.10B
Enterprise Value
$70.26B
P/E Ratio
21.9x
PEG Ratio
19.7x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+1.9%
Gross Margin
+59.4%
Operating Margin
+20.2%
Net Margin
+14.5%
EPS Growth
-0.3%
Financial Health
Cash/Price Ratio
+2.3%
Current Ratio
0.9x
Debt/Equity
680.0x
ROE
+293.6%
ROA
+15.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Colgate-Palmolive Co. (CL) Business Model
About Colgate-Palmolive Co.
What They Do
Global consumer products company focused on personal care.
Business Model
Colgate-Palmolive Co. generates revenue through the sale of a diverse range of consumer products, including oral care, personal care, home care, and pet nutrition. The company markets its products to consumers in over 200 countries via supermarkets, drug stores, and e-commerce platforms, ensuring widespread accessibility and convenience.
Additional Information
Founded in 1806 and headquartered in New York City, Colgate-Palmolive is a well-established player in the consumer staples sector. Its flagship products, such as toothpaste and pet food, contribute to its strong market presence and brand loyalty, highlighting its stability and influence in the industry.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
34,000
CEO
Mr. Noel R. Wallace
Country
United States
IPO Year
1977
Website
www.colgatepalmolive.comColgate-Palmolive Co. (CL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Implied Volatility Surging for Colgate-Palmolive Stock Options
Investors need to pay close attention to CL stock based on the movements in the options market lately.
Dec 05, 2025
By Zacks Equity Research
Tale of the Tape
National Vision (EYE) Up 19.9% Since Last Earnings Report: Can It Continue?
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 05, 2025
By Zacks Equity Research
Realtime BLOG
Procter & Gamble's $1.5B Cost Savings Plan: Efficacy or Overreach?
PG's $1.5B cost-savings push aims to protect margins and fuel innovation as the company balances efficiency risks with the need to sustain its competitive edge.
Dec 02, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Colgate-Palmolive Company (CL) presented at the Morgan Stanley Global Consumer & Retail Conference, discussing its business strategies and outlook for 2025.
Why It Matters
Colgate-Palmolive's presentation at a major conference signals its strategic direction and outlook, influencing investor sentiment and potential stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Colgate-Palmolive's diverse category system enhances its competitive edge, with Hill's stabilizing demand supporting its broader portfolio, especially in economic slowdowns.
Why It Matters
Colgate-Palmolive's diverse categories enhance its competitive edge, ensuring stability and resilience in demand, which may lead to stronger financial performance during economic downturns.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Colgate-Palmolive (CL) has a 62-year dividend growth history and recently rebounded from earnings declines. Strong institutional buying and positive technical signals indicate growth momentum.
Why It Matters
Colgate-Palmolive's strong dividend history and recent earnings rebound, coupled with institutional buying and positive technical signals, indicate potential growth and stability for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
5 Top Dividend Stocks to Buy in November
13 days ago
Quick Summary
Investors are advised to buy and hold companies that consistently increase dividends, with opportunities in energy, healthcare, consumer staples, and technology sectors.
Why It Matters
Rising dividends signal financial health and stability, attracting long-term investors. Opportunities across various sectors indicate potential for growth and income generation.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Colgate-Palmolive is focusing on accelerated, science-driven innovation and a global relaunch of Colgate Total to address declining volumes and restore growth momentum.
Why It Matters
Colgate's focus on innovation and a relaunch aims to boost sales amidst declining volumes, potentially enhancing future revenue and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Don't Give Up on Dividend Stocks. 5 Dividend Kings Down Between 5% and 33% to Buy in November
18 days ago
Quick Summary
Consumer staples stocks are declining, indicating a gap between the consumer economy and the stock market. Dividend Kings are recommended for investors seeking reliable dividends and value.
Why It Matters
Declining consumer staples stocks signal potential economic weakness, while reliable Dividend Kings offer stability and value, attracting cautious investors amid market volatility.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About CL Stock
What is Colgate-Palmolive Co.'s (CL) stock forecast for 2026?
Based on our analysis of 29 Wall Street analysts, Colgate-Palmolive Co. (CL) has a median price target of $88.00. The highest price target is $95.00 and the lowest is $77.00.
Is CL stock a good investment in 2026?
According to current analyst ratings, CL has 13 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $78.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CL stock?
Wall Street analysts predict CL stock could reach $88.00 in the next 12 months. This represents a 12.7% increase from the current price of $78.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Colgate-Palmolive Co.'s business model?
Colgate-Palmolive Co. generates revenue through the sale of a diverse range of consumer products, including oral care, personal care, home care, and pet nutrition. The company markets its products to consumers in over 200 countries via supermarkets, drug stores, and e-commerce platforms, ensuring widespread accessibility and convenience.
What is the highest forecasted price for CL Colgate-Palmolive Co.?
The highest price target for CL is $95.00 from Filippo Falorni at Citigroup, which represents a 21.7% increase from the current price of $78.07.
What is the lowest forecasted price for CL Colgate-Palmolive Co.?
The lowest price target for CL is $77.00 from Chris Carey at Wells Fargo, which represents a -1.4% decrease from the current price of $78.07.
What is the overall CL consensus from analysts for Colgate-Palmolive Co.?
The overall analyst consensus for CL is bullish. Out of 29 Wall Street analysts, 13 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $88.00.
How accurate are CL stock price projections?
Stock price projections, including those for Colgate-Palmolive Co., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 6:42 AM UTC